Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1367819

Dietary galactose exacerbates autoimmune neuroinflammation via advanced glycation end product-mediated neurodegeneration

Provisionally accepted
Stefanie Haase Stefanie Haase 1*Kristina Kuhbandner Kristina Kuhbandner 2Florian Mühleck Florian Mühleck 2Barbara Gisevius Barbara Gisevius 3David Freudenstein David Freudenstein 1Sarah Hirschberg Sarah Hirschberg 3De-Hyung Lee De-Hyung Lee 1Stefanie Kürten Stefanie Kürten 4Ralf Gold Ralf Gold 3Aiden Haghikia Aiden Haghikia 5Ralf A. Linker Ralf A. Linker 1
  • 1 Department of Neurology, University Hospital Regensburg, Regensburg, Bavaria, Germany
  • 2 Department of Neurology, University Hospital Erlangen, Erlangen, Bavaria, Germany
  • 3 Department of Neurology, St. Josef-Hospital, Bochum, North Rhine-Westphalia, Germany
  • 4 Institute of Neuroanatomy, Faculty of Medicine, University of Bonn and University Hospital Bonn, Bonn, Germany
  • 5 Department of Neurology, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany

The final, formatted version of the article will be published soon.

    Background: Recent studies provide increasing evidence for a relevant role of lifestyle factors including diet in the pathogenesis of neuroinflammatory diseases such as multiple sclerosis (MS). While the intake of saturated fatty acids and elevated salt worsen the disease outcome in the experimental model of MS by enhanced inflammatory but diminished regulatory immunological processes, sugars as additional prominent components in our daily diet have only scarcely been investigated so far. Apart from glucose and fructose, galactose is a common sugar in the so-called Western diet. Methods: We investigated the effect of a galactose-rich diet during neuroinflammation using myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (MOG-EAE) as a model disease. We investigated peripheral immune reactions and inflammatory infiltration by ex vivo flow cytometry analysis and performed histological staining of the spinal cord to analyze effects of galactose in the central nervous system (CNS). We analyzed the formation of advanced glycation end products (AGEs) by fluorescence measurements and investigated galactose as well as galactoseinduced AGEs in oligodendroglial cell cultures and induced pluripotent stem cell-derived primary neurons (iPNs). Results: Young mice fed a galactose-rich diet displayed exacerbated disease symptoms in the acute phase of EAE as well as impaired recovery in the chronic phase. Galactose did not affect peripheral immune reactions or inflammatory infiltration into the CNS, but resulted in increased demyelination, oligodendrocyte loss and enhanced neuro-axonal damage. Ex vivo analysis revealed an increased apoptosis of oligodendrocytes isolated from mice adapted on a galactose-rich diet. In vitro, treatment of cells with galactose neither impaired the maturation nor survival of oligodendroglial cells or iPNs.However, incubation of proteins with galactose in vitro led to the formation AGEs, that were increased in the spinal cord of EAE-diseased mice fed a galactose-rich diet. In oligodendroglial and neuronal cultures, treatment with galactose-induced AGEs promoted enhanced cell death compared to control treatment. Conclusion: These results imply that galactose-induced oligodendrocyte and myelin damage during neuroinflammation may be mediated by AGEs, thereby identifying galactose and its reactive products as potential dietary risk factors for neuroinflammatory diseases such as MS.

    Keywords: Galactose, Advanced glycation end products, Neuroinflammation, MOG-EAE, oligodendrocytes, human induced primary neurons, Multiple Sclerosis

    Received: 09 Jan 2024; Accepted: 26 Jul 2024.

    Copyright: © 2024 Haase, Kuhbandner, Mühleck, Gisevius, Freudenstein, Hirschberg, Lee, Kürten, Gold, Haghikia and Linker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Stefanie Haase, Department of Neurology, University Hospital Regensburg, Regensburg, Bavaria, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.